{"groups":[{"description":"Olaparib tablets 300mg taken orally twice daily.","id":"FG000","title":"Olaparib"},{"description":"Placebo tablets taken orally twice daily.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"143"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"36"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"78"},{"groupId":"FG001","numSubjects":"64"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"697"},{"groupId":"FG001","numSubjects":"666"}],"type":"Ongoing study at the data cut-off (DCO3: 05Jun2024)"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}],"type":"Other (e.g investigators decision, protocol deviation, randomised by mistake)"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"921"},{"groupId":"FG001","numSubjects":"915"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"921"},{"groupId":"FG001","numSubjects":"915"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients with unknown germline BRCA (gBRCA) mutation status prior to randomisation underwent Screening Part 1 to ascertain gBRCA mutation status during, or prior to, neoadjuvant/adjuvant chemotherapy. All patients with known gBRCA mutation status (including those found through Screening Part 1) underwent Screening Part 2.","recruitmentDetails":"The first patient was enrolled on 22 April 2014. Patients were randomised from 554 centres in 23 countries worldwide."}